Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 5, 2025—The College of American Pathologists and the Joint Commission have reached an agreement permitting advance notification of laboratory inspections at Joint Commission–accredited hospitals.
June 4, 2025—The Food and Drug Administration has approved the de novo application for Randox Laboratories’ first companion diagnostic, the Randox ConcizuTrace ELISA.
May 27, 2025—Pillar Biosciences announced it has finalized $34.5 million in funding, including a strategic investment from Illumina and structured financing from Soleus Capital and investments from existing investors.
May 21, 2025—Tribun Health announced that its flagship web-based image management system, CaloPix, has received FDA 510(k) clearance for use with the Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
May 19, 2025—Fujirebio announced that the FDA has granted 510(k) clearance for its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio test.
May 16, 2025—Roche announced FDA approval for the Ventana MET (SP44) RxDx assay, the first companion diagnostic approved to aid in determining MET protein expression in patients with non-small cell lung cancer. These patients may now be eligible for treatment with AbbVie’s c-Met targeted therapy Emrelis (telisotuzumab vedotin-tllv).
May 14, 2025—AbbVie announced that Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the FDA for the treatment of adult patients with locally advanced or metastatic, nonsquamous non-small cell lung cancer with high c-Met protein overexpression who have received a prior systemic therapy.
May 8, 2025—Ibex Medical Analytics reports that a study conducted at Ohio State University Wexner Medical Center confirms that Ibex Breast, an AI-powered diagnostic support solution, significantly improves accuracy and efficiency in evaluating breast pathology cases (Tahir M, et al. Clin Breast Cancer. Published online March 26, 2025).
April 29, 2025—Roche announced that the FDA granted breakthrough device designation for the Ventana TROP2 (EPR20043) RxDx device, a computational pathology device.
April 24, 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States.
